# CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

> **NCT05681351** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 885 (actual)

## Conditions studied

- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** Olezarsen

## Key facts

- **NCT ID:** NCT05681351
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-13
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 885 (ACTUAL)
- **Last updated:** 2025-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05681351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05681351, "CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT05681351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*